Bio Protocol has launched OpenLabs, a platform that combines AI-assisted research development, community funding, and on-chain governance as its ecosystem exceeds $33 million in capital raised.
summary
- Bio Protocol has launched OpenLabs, which brings together AI-assisted research development, collaboration and funding into a single platform.
- Researchers can obtain funding through community voting, with BIO token holders participating in governance decisions.
- Bio Protocol said its BIO Genesis initiative has raised more than $33 million to support decentralized scientific projects.
According to Bio Protocol, the platform was presented on June 19 during DeSci.Berlin 2026, an event held at KÖNIG GALERIE as part of Berlin Blockchain Week.
OpenLabs is designed to allow researchers to develop scientific ideas, coordinate with contributors and seek funding through a single interface rather than relying on separate grant applications, governance platforms and collaboration tools, the project said.
At the event, Bio Protocol presented OpenLabs as an alternative to traditional research funding processes, which often involve long review cycles and institutional oversight. Community members can vote on research proposals while an AI-powered workflow helps researchers develop and improve projects, the project said.
Although the biometric protocol was launched (the biography) continued to trade lower alongside the broader cryptocurrency market. The token fell more than 8% over the past 24 hours as investors took stock of the situation Falcon dialect Adopted by Federal Reserve Chairman Kevin Warsh and the uncertainty surrounding the implementation of the proposal Framework for US-Iranian peace.
OpenLabs combines research collaboration with funding decisions
Under the model described by Bio Protocol, researchers and community participants work within the same platform where project development and funding decisions are made. The BIO token acts as a governance and utility asset used for voting and participation in the ecosystem.
Bio Protocol highlighted two projects during the launch. According to the team, RheumaAI is being developed as an AI agent focused on rheumatology research, while PeptAI is focused on peptide discovery.
OpenLabs integrates AI-driven processes into scientific collaboration while allowing token holders and community members to participate in funding decisions, the project said. Instead of relying solely on traditional grant committees, project proposals can be reviewed and supported through the community governance mechanisms built into the platform.
DeSci.Berlin previously served as a venue for decentralized scientific initiatives. According to Bio Protocol, previous editions of the conference have helped incubate projects, including Molecule Labs.
Bio Protocol is expanding its decentralized scientific infrastructure
OpenLabs forms part of Bio Protocol’s current decentralized science strategy. According to the project, an infrastructure has been developed that uses tokenized intellectual property and BioDAOs to direct funding towards biotechnology programs and scientific research.
Bio Protocol said its BIO Genesis initiative has raised more than $33 million to date. The project describes BIO Genesis as a fundraising mechanism that supports research-focused organizations operating within its ecosystem.
Bio Protocol’s work with AI research tools predates OpenLabs. In August 2025 the project Fired Sell Ignition to Aubrai, a decentralized BioAgent developed in collaboration with VitaDAO for longevity research. According to Bio Protocol, O’Pray works as an AI associate scientist capable of generating hypotheses and helping design laboratory experiments.
According to Bio Protocol, the decentralized science sector seeks to apply blockchain-based systems for research funding, governance, and intellectual property management. Supporters of the model argue that transparent funding records and community engagement can provide alternatives to traditional research funding structures.
Regulatory issues remain a potential challenge as these models evolve. The symbolic intellectual property associated with biotechnology projects intersects with securities regulations, patent frameworks, and pharmaceutical regulatory requirements.
As research programs progress from early stage concepts to commercial development, legal obligations and commitments can become more complex for projects operating in the decentralized science sector.
